Refine
Year of publication
- 2020 (18) (remove)
Document Type
- Article (15)
- Doctoral Thesis (3)
Has Fulltext
- yes (18)
Is part of the Bibliography
- no (18)
Keywords
- - (9)
- stroke (4)
- Delphi study (3)
- clinical (3)
- motor rehabilitation (3)
- outcome measures (3)
- basal ganglia (2)
- cerebellum (2)
- chemical senses (2)
- network (2)
Institute
- Klinik und Poliklinik für Neurologie (18) (remove)
Publisher
- Frontiers Media S.A. (9)
- MDPI (3)
- Wiley (2)
- SAGE Publications (1)
Hintergrund: VPS ist ein bekannter Inhibitor der HDAC. In den zurückliegenden Jahren sind mehrere Publikationen erschienen, die VPS eine bedeutende Rolle in Bezug auf eine neuroprotektive Wirkung zugeschrieben haben. Jedoch sind in diesem Zeitraum auch gegenteilige Ergebnisse veröffentlicht worden. In bisherigen eigenen Voruntersuchungen sahen wir, dass VPS weder neuroprotektive noch zytotoxische Effekte hervorgerufen hatte. In der vorliegenden Arbeit untersuchten wir unter Verwendung von Dosierungen, die dem therapeutischen Wirkspiegel von VPS entsprachen, ob VPS die neurotoxische Wirkung von MPP+ inhibieren konnte.
Hypothese: Die vorliegende Dissertation soll einen Beitrag zur Erweiterung des Verständnisses der Auswirkungen einer VPS-Gabe auf das Verhalten neuraler Vorläuferzellen liefern. Insbesondere sollte die postulierte neuroprotektive Wirkung von VPS gegenüber dem neurotoxischen Agens MPP+ evaluiert werden.
Methoden: Die fmNPZ werden in einer feuchtigkeitsgesättigten Atmosphäre in einem Expansionsmedium propagiert. Die Differenzierung erfolgt auf PLL beschichteten Kulturplatten in P4-8F Medium mit ohne VPS, 100μg/ml VPS und 200μg/ml VPS für bis zu 96 Stunden. Zur Detektion neuroprotektiver Effekte von VPS verwendeten wir einen Zytotoxizitästest: neben der simultanen Gabe von MPP+ und VPS erfolgte eine 24-stündige Vorbehandlung mit VPS, bevor MPP+ appliziert wurde. Zur Auswertung der Tests kamen histochemische Verfahren (PI/bisBenzimid-Färbung) zur Anwendung. Zur Evaluation des Proliferationspotenzials der fmNPZ unter Anwendung von VPS nutzen wir immunhistochemische Verfahren nach Standardprotokollen unter Verwendung folgender Antikörper: Maus Anti-BrdU (Konzentration: 60μl 5mM Stocklösung/ml), Kaninchen Anti-Ki-67 (1:500) und entsprechende Floureszenz-gelabelte Sekundär-AK (1:500).
Ergebnisse: 100μg/ml als auch 200μg/ml VPS - als Einzelsubstanz - bewirkten nach 96 Stunden Differenzierungszeit eine signifikante Zunahme an avitalen Zellen. MPP+ - als Einzelsubstanz - zeigte die erwartete konzentrationsabhängige signifikante Zunahme an nekrotischen Zellen. Nach Simultangabe von MPP+/VPS bewirkte VPS sowohl unter Expansions- als auch unter Differenzierungsbedingungen keinen signifikant neuroprotektiven Effekt gegenüber MPP+. Nach 24-stündiger Vorbehandlung mit VPS sahen wir unter Expansionsbedingungen nach Applikation von 200μg/ml VPS einen die Toxizität von MPP+ verstärkenden Effekt. Unter Differenzierungsbedingungen bewirkte erst die Zugabe von 60μM MPP+ und eine weitere gemeinsame Kultivierungszeit von 72 Stunden einen signifikanten Anstieg an avitalen Zellen.
Die Proliferationskapazität der fmNPZ war nach Zugabe von 100μg/ml VPS nicht verändert.
Schlussfolgerungen: Zur Klärung der Frage welche Effekte VPS auf das Verhalten prädopaminerger, neuraler Progenitorzellen auslöst, konnte diese Arbeit einen weiteren wichtigen Beitrag leisten. Das gesetzte Ziel konnten wir somit erreichen.
Die Therapie neurodegenerativer Erkrankungen wie die des Morbus Parkinson besteht derzeit in einer rein symptomatischen Behandlung ohne die Progredienz der Erkrankungen deutlich verlangsamen oder gar stoppen zu können. Eine kausale Therapie wie zum Beispiel eine zellbasierte Ersatztherapie konnte bis dato noch nicht erfolgreich etabliert werden.
Unsere Arbeit liefert einen weiteren Beitrag zum Verständnis der Wirkungen von VPS auf das Differenzierungs- und Expansionsverhalten prädopaminerger, neuraler Progenitorzellen.
Unter Berücksichtigung des in dieser Arbeit verwendeten Versuchsaufbaus kann postuliert werden, dass VPS keinen neuroprotektiven Effekt auf die fmNPZ ausübt. In höherer Dosierung als die die dem therapeutischen Wirkspiegel von VPS entsprechen, konnte unter bestimmten Bedingungen ein zytotoxischer Effekt nachgewiesen werden. Diese Ergebnisse passen sowohl zu früheren Publikationen mit anderen Zellsystemen, die einen toxischen Effekt von VPS beobachtet hatten, als auch zu den Ergebnissen eigener Voruntersuchungen.
Die gewonnenen Erkenntnisse sind unter dem Aspekt der zukünftigen Entwicklung Stammzell-basierter Zellersatztherapien als auch der pharmakologischen Beeinflussung der in vivo Neurogenese von Bedeutung, weil diese Erkenntnisse einerseits Wirkungen von VPS auf Ebene neuraler Vorläuferzellen aufzeigen und andererseits daraus folgend eine kritische Evaluation der Anwendung von VPS ermöglicht.
Wir leben in einer älter werdenden Gesellschaft, in der die gesundheitlichen Herausforderungen u.a. durch zerebrovaskuläre Erkrankungen steigen. Ein Schlaganfall wird dank exzellenter Akutversorgung zwar oftmals überlebt, ein Großteil der Patienten hat jedoch starke Funktionseinbußen und benötigt rehabilitative Unterstützung, um eine persistierende Behinderung zu vermeiden. Oft ist für längere Zeit sowohl in der akuten als auch in der chronischen Phase nach Schlaganfall eine optimale Therapie unabdingbar, um dem Patienten das Wiedererlangen einer möglichst hohen Selbstständigkeit im Alltag zu ermöglichen.
Im Rahmen der vorliegenden Arbeit wird eine evidenzbasierte rehabilitative Behandlung der Armparese nach Schlaganfall durch eine systematische Suche und kritische Würdigung sowie Synthese der besten verfügbaren Evidenz aus klinischen Studien charakterisiert. Zu diesem Zweck wurden bei einer systematischen Literaturrecherche für den Zeitraum vom 12.2003 bis 11.2013 932 Referenzen in der Fachdatenbank PubMed identifiziert. Aus diesen wurden nach Ein- und Ausschlusskriterien 202 Studien für die Fragestellung relevante randomisierte kontrollierte Studien selektiert. Anschließend fand für jede RKS eine standardisierte Datenextraktion, kritische Würdigung der methodischen Studienqualität (Critical appraisal) sowie die Formulierung der ableitbaren klinischen Schlussfolgerungen statt. Daran anknüpfend erfolgte für einzelne Therapieverfahren (über alle RKS zu einem Thema hinweg) eine Ableitung von konkreten Empfehlungen für die klinische Praxis. Für die Bewertung der Qualität der Evidenz der eingeschlossenen Quellen und die Graduierung der Empfehlungsstärke wurden die Standards der Grading of Recommendations Assessment, Development and Evaluation (kurz GRADE) genutzt.
Die Evidenz belegt, dass eine ganze Reihe therapeutischer Verfahren die Erholung der Armfunktion nach Schlaganfall unterstützen kann. Eine Überlegenheit gegenüber anderen Verfahren wurde für nur wenige Therapien gezeigt, wie z.B. für die Constraint-induced movement therapy und das schädigungsorientierte Training in Form des Arm-Fähigkeits- und Arm-Basis-Trainings (Therapie ohne Geräte), die Arm-Robot-Therapie oder die Spiegeltherapie (Therapie mit Geräten). Abschließend erhält der Leser eine Art ‚Rezeptblock‘, anhand dessen eine mögliche und evidenzbasierte Therapie bzw. Therapiealternative direkt abgelesen werden kann und der die praktische Umsetzung der evidenzbasierten Empfehlungen fördern soll. Gegliedert wurde der ‚Rezeptblock‘ nach der Schwere der Armlähmung (leichte, mittlere und schwere Parese) und der Chronizität der Schlaganfallresiduen (akute, subakute, chronische Phase).
Der aktuelle demografische Wandel in Deutschland zeigt eine erhöhte Lebenserwartung und damit einen Anstieg an altersassoziierten Erkrankungen wie dem Schlaganfall. Eine mögliche Folge ist die Armparese, welche eine gravierende Behinderung bei der Ausführung alltäglicher Handlungen darstellt. Dadurch kommt der motorischen Rehabilitation mit dem Ziel der Wiederherstellung der Alltagstauglichkeit eine besonders wichtige Rolle zu.
Unter zahlreichen Therapiekonzepten ist für das Arm-Fähigkeits-Training (AFT), welches einzeln verschiedene sensomotorische Armfähigkeiten anspricht und das motorische Lernen induziert, eine gute Wirksamkeit belegt.
In Studien konnte gezeigt werden, dass eine nicht-invasive Hirnstimulation in Form einer repetitiven transkraniellen Magnetstimulation (rTMS), genauer der intermittierenden Theta-Burst-Stimulation (iTBS), vorübergehend die lokal kortikale Erregbarkeit des stimulierten Areals erhöhen (Huang et al., 2005) und dadurch gegebenenfalls auch das nachfolgende trainingsinduzierte Lernen beeinflussen kann. Das Wissen über mögliche „Priming“-Effekte von iTBS auf das motorische Lernen bei Gesunden kann helfen, zielgerichtete therapeutische Anwendungen für Patienten nach einem Schlaganfall zu entwickeln.
Ziel dieser Untersuchung war es festzustellen, ob das exzitatorische „Priming“ mit iTBS über dem primären motorischen Kortex (M1) oder dem primären somatosensorischen Kortex (S1) unmittelbar vor einer täglichen Trainingseinheit mit AFT (über vier Tage) für den linken Arm bei gesunden rechtshändigen Probanden die sensomotorische Lerndynamik verbessern kann.
Zu diesem Zweck wurde ein Training des linken, nicht-dominanten Arms von 18 jungen und gesunden Probanden mithilfe von acht unterschiedlichen motorischen Aufgaben (AFT) einmal pro Tag für insgesamt fünf Tage durchgeführt. Mit Ausnahme des ersten Tages (Baseline) erfolgte das Training nach der Applikation einer exzitatorischen Form der repetitiven transkraniellen Magnetstimulation (iTBS). Die Stimulation wurde je nach randomisierter Gruppenzuordnung entweder über M1 oder S1 rechts oder als Sham-Stimulation, um einen möglichen Placebo-Effekt auszuschließen, über M1 rechts durchgeführt.
Die Hauptkomponentenanalyse der Daten zum motorischen Verhalten ergab acht
unabhängige motorische Komponenten, die den acht trainierten Aufgaben entsprachen. AFT induzierte motorisches Lernen über alle Fähigkeiten hinweg mit einem Generalisationseffekt auf eine nicht-trainierte Aufgabe der Fingergeschicklichkeitm(Nine-Hole-Peg-Test,ccNHPT).
Probanden, die iTBS (entweder über M1 oder S1) erhielten, zeigten im Vergleich zur Sham-Stimulation sowohl eine bessere Leistung bei den AFT-Aufgaben während der Trainingsdauer als auch eine größere Verbesserung der nicht-trainierten Fingergeschicklichkeitsaufgabe (NHPT) für den trainierten linken Arm nach Trainingsende.
Daraus resultiert, dass die exzitatorische repetitive transkranielle Magnetstimulation in Form von iTBS über M1 oder S1 das motorische Lernen über verschiedene sensomotorische Fähigkeiten hinweg verbessern kann.
Auch wenn die verstärkenden Effekte eines exzitatorischen „Priming“ absolut gesehen klein waren, so geben sie dennoch Grund zur Annahme, dass darin auch ein therapeutisches Potenzial für die Armrehabilitation nach Schlaganfall liegt. Ob das so ist, wäre jedoch mit geeigneten klinischen Studien zu untersuchen.
Die Ergebnisse des Promotionsvorhabens wurden in einer Peer-Review-Zeitschrift publiziert (Platz et al., 2018a).
Age-related deterioration in white and gray matter is linked to cognitive deficits. Reduced microstructure of the fornix, the major efferent pathway of the hippocampus, and volume of the dentate gyrus (DG), may cause age-associated memory decline. However, the linkage between these anatomical determinants and memory retrieval in healthy aging are poorly understood. In 30 older adults, we acquired diffusion tensor and T1-weighted images for individual deterministic tractography and volume estimation. A memory task, administered outside of the scanner to assess retrieval of learned associations, required discrimination of previously acquired picture-word pairs. The results showed that fornix fractional anisotropy (FA) and left DG volumes were related to successful retrieval. These brain-behavior associations were observed for correct rejections, but not hits, indicating specificity of memory network functioning for detecting false associations. Mediation analyses showed that left DG volume mediated the effect of fornix FA on memory (48%), but not vice versa. These findings suggest that reduced microstructure induces volume loss and thus negatively affects retrieval of learned associations, complementing evidence of a pivotal role of the fornix in healthy aging. Our study offers a neurobehavioral model to explain variability in memory retrieval in older adults, an important prerequisite for the development of interventions to counteract cognitive decline.
Objectives: Navigated transcranial magnetic stimulation (nTMS) provides significant benefits over classic TMS. Yet, the acquisition of individual structural magnetic resonance images (MRIindividual) is a time-consuming, expensive, and not feasible prerequisite in all subjects for spatial tracking and anatomical guidance in nTMS studies. We hypothesize that spatial transformation can be used to adjust MRI templates to individual head shapes (MRIwarped) and that TMS parameters do not differ between nTMS using MRIindividual or MRIwarped.
Materials and Methods: Twenty identical TMS sessions, each including four different navigation conditions, were conducted in 10 healthy subjects (one female, 27.4 ± 3.8 years), i.e., twice per subject by two researchers to additionally assess interrater reliabilities. MRIindividual were acquired for all subjects. MRIwarped were obtained through the spatial transformation of a template MRI following a 5-, 9-and 36-point head surface registration (MRIwarped_5, MRIwarped_9, MRIwarped_36). Stimulation hotspot locations, resting motor threshold (RMT), 500 μV motor threshold (500 μV-MT), and mean absolute motor evoked potential difference (MAD) of primary motor cortex (M1) examinations were compared between nTMS using either MRIwarped variants or MRIindividual and non-navigated TMS.
Results: M1 hotspots were spatially consistent between MRIindividual and MRIwarped_36 (insignificant deviation by 4.79 ± 2.62 mm). MEP thresholds and variance were also equivalent between MRIindividual and MRIwarped_36 with mean differences of RMT by −0.05 ± 2.28% maximum stimulator output (%MSO; t(19) = −0.09, p = 0.923), 500 μV-MT by −0.15 ± 1.63%MSO (t(19) = −0.41, p = 0.686) and MAD by 70.5 ± 214.38 μV (t(19) = 1.47, p = 0.158). Intraclass correlations (ICC) of motor thresholds were between 0.88 and 0.97.
Conclusions: NTMS examinations of M1 yield equivalent topographical and functional results using MRIindividual and MRIwarped if a sufficient number of registration points are used.
One of the great challenges the world faces in terms of health care is the increasing number of
people living with neuro-disabilities that affect their ability to participate in societal activities.
Various neurological conditions such as stroke, multiple sclerosis, or Parkinson’s disease, to name
just a few, change cognitive, sensory, or motor capacities, alter the emotional well-being of those
affected, and lead to disability in their everyday lives.
Over the last few decades, aging populations and reduced mortality in many regions of the world
have increased the number of people living with neuro-disabilities considerably, an effect that is
still ongoing (1): for 2017, the worldwide prevalence of stroke (thousands) has been estimated to
be as high as 104178.7 (95% confidence interval, 95% CI 98454.0–110125.0), and years lived with
disabilities (YLD) (counts in thousands) caused by stroke were reported to amount to 18695.4
(95% CI 13,574–23686.9). The stroke-related increase in YLD (percentage change in counts)
was 40% (95% CI 38.4–41.4) from 1990 to 2007 and another 43.6% (39.6–47.8) during only 10
years from 2007 to 2017. The numbers are similarly impressive for other neurological disorders
(i.e., dementias, Parkinson’s disease, epilepsy, multiple sclerosis, motor neuron disease, headache
disorders, and others). Taken together, their worldwide prevalence (in thousands) in 2017 was
3121435.3 (95% CI 2951124.5–3316268.0), while YLD (thousands) in 2017 were 3121435.3 (95%
CI 2951124.5–3316268.0), with an increase in YLD by 35.1% (95% CI 31.9–38.1) from 1990 to 2007
and by a further 17.8% (95% CI 15.8–20.2) from 2007 to 2017.
These numbers not only demonstrate the huge global burden of disease and prevailing
neuro-disabilities, but they indicate a considerable increase in the number of people living with
neuro-disabilities with an accelerating dynamic over time (for stroke).
Introduction: Outcome measures are key to tailor rehabilitation goals to the stroke patient's individual needs and to monitor poststroke recovery. The large number of available outcome measures leads to high variability in clinical use. Currently, an internationally agreed core set of motor outcome measures for clinical application is lacking. Therefore, the goal was to develop such a set to serve as a quality standard in clinical motor rehabilitation poststroke.
Methods: Outcome measures for the upper and lower extremities, and activities of daily living (ADL)/stroke-specific outcomes were identified and presented to stroke rehabilitation experts in an electronic Delphi study. In round 1, clinical feasibility and relevance of the outcome measures were rated on a 7-point Likert scale. In round 2, those rated at least as “relevant” and “feasible” were ranked within the body functions, activities, and participation domains of the International Classification of Functioning, Disability, and Health (ICF). Furthermore, measurement time points poststroke were indicated. In round 3, answers were reviewed in reference to overall results to reach final consensus.
Results: In total, 119 outcome measures were presented to 33 experts from 18 countries. The recommended core set includes the Fugl–Meyer Motor Assessment and Action Research Arm Test for the upper extremity section; the Fugl–Meyer Motor Assessment, 10-m Walk Test, Timed-Up-and-Go, and Berg Balance Scale for the lower extremity section; and the National Institutes of Health Stroke Scale, and Barthel Index or Functional Independence Measure for the ADL/stroke-specific section. The Stroke Impact Scale was recommended spanning all ICF domains. Recommended measurement time points are days 2 ± 1 and 7; weeks 2, 4, and 12; 6 months poststroke and every following 6th month.
Discussion and Conclusion: Agreement was found upon a set of nine outcome measures for application in clinical motor rehabilitation poststroke, with seven measurement time points following the stages of poststroke recovery. This core set was specifically developed for clinical practice and distinguishes itself from initiatives for stroke rehabilitation research. The next challenge is to implement this clinical core set across the full stroke care continuum with the aim to improve the transparency, comparability, and quality of stroke rehabilitation at a regional, national, and international level.
Introduction: Outcome measures are key to tailor rehabilitation goals to the stroke patient's individual needs and to monitor poststroke recovery. The large number of available outcome measures leads to high variability in clinical use. Currently, an internationally agreed core set of motor outcome measures for clinical application is lacking. Therefore, the goal was to develop such a set to serve as a quality standard in clinical motor rehabilitation poststroke.
Methods: Outcome measures for the upper and lower extremities, and activities of daily living (ADL)/stroke-specific outcomes were identified and presented to stroke rehabilitation experts in an electronic Delphi study. In round 1, clinical feasibility and relevance of the outcome measures were rated on a 7-point Likert scale. In round 2, those rated at least as “relevant” and “feasible” were ranked within the body functions, activities, and participation domains of the International Classification of Functioning, Disability, and Health (ICF). Furthermore, measurement time points poststroke were indicated. In round 3, answers were reviewed in reference to overall results to reach final consensus.
Results: In total, 119 outcome measures were presented to 33 experts from 18 countries. The recommended core set includes the Fugl–Meyer Motor Assessment and Action Research Arm Test for the upper extremity section; the Fugl–Meyer Motor Assessment, 10-m Walk Test, Timed-Up-and-Go, and Berg Balance Scale for the lower extremity section; and the National Institutes of Health Stroke Scale, and Barthel Index or Functional Independence Measure for the ADL/stroke-specific section. The Stroke Impact Scale was recommended spanning all ICF domains. Recommended measurement time points are days 2 ± 1 and 7; weeks 2, 4, and 12; 6 months poststroke and every following 6th month.
Discussion and Conclusion: Agreement was found upon a set of nine outcome measures for application in clinical motor rehabilitation poststroke, with seven measurement time points following the stages of poststroke recovery. This core set was specifically developed for clinical practice and distinguishes itself from initiatives for stroke rehabilitation research. The next challenge is to implement this clinical core set across the full stroke care continuum with the aim to improve the transparency, comparability, and quality of stroke rehabilitation at a regional, national, and international level.
Background: Stroke patients are at risk of acquiring secondary infections due to stroke-induced immune suppression (SIIS). Immunosuppressive cells comprise myeloid-derived suppressor cells (MDSCs) and immunosuppressive interleukin 10 (IL-10)-producing monocytes. MDSCs represent a small but heterogeneous population of monocytic, polymorphonuclear (or granulocytic), and early progenitor cells (“early” MDSC), which can expand extensively in pathophysiological conditions. MDSCs have been shown to exert strong immune-suppressive effects. The role of IL-10-producing immunosuppressive monocytes after stroke has not been investigated, but monocytes are impaired in oxidative burst and downregulate human leukocyte antigen—DR isotype (HLA-DR) on the cell surface.
Objectives: The objective of this work was to investigate the regulation and function of MDSCs as well as the immunosuppressive IL-10-producing monocytes in experimental and human stroke.
Methods: This longitudinal, monocentric, non-interventional prospective explorative study used multicolor flow cytometry to identify MDSC subpopulations and IL-10 expression in monocytes in the peripheral blood of 19 healthy controls and 27 patients on days 1, 3, and 5 post-stroke. Quantification of intracellular STAT3p and Arginase-1 by geometric mean fluorescence intensity was used to assess the functionality of MDSCs. In experimental stroke induced by electrocoagulation in middle-aged mice, monocytic (CD11b+Ly6G−Ly6Chigh) and polymorphonuclear (CD11b+Ly6G+Ly6Clow) MDSCs in the spleen were analyzed by flow cytometry.
Results: Compared to the controls, stroke patients showed a relative increase in monocytic MDSCs (percentage of CD11b+ cells) in whole blood without evidence for an altered function. The other MDSC subgroups did not differ from the control. Also, in experimental stroke, monocytic, and in addition, polymorphonuclear MDSCs were increased. The numbers of IL-10-positive monocytes did not differ between the patients and controls. However, we provide a new insight into monocytic function post-stroke since we can report that a differential regulation of HLA-DR and PD-L1 was found depending on the IL-10 production of monocytes. IL-10-positive monocytes are more activated post-stroke, as indicated by their increased HLA-DR expression.
Conclusions: MDSC and IL-10+ monocytes can induce immunosuppression within days after stroke.
Introduction: Outcome measures are key to tailor rehabilitation goals to the stroke patient's individual needs and to monitor poststroke recovery. The large number of available outcome measures leads to high variability in clinical use. Currently, an internationally agreed core set of motor outcome measures for clinical application is lacking. Therefore, the goal was to develop such a set to serve as a quality standard in clinical motor rehabilitation poststroke.
Methods: Outcome measures for the upper and lower extremities, and activities of daily living (ADL)/stroke-specific outcomes were identified and presented to stroke rehabilitation experts in an electronic Delphi study. In round 1, clinical feasibility and relevance of the outcome measures were rated on a 7-point Likert scale. In round 2, those rated at least as “relevant” and “feasible” were ranked within the body functions, activities, and participation domains of the International Classification of Functioning, Disability, and Health (ICF). Furthermore, measurement time points poststroke were indicated. In round 3, answers were reviewed in reference to overall results to reach final consensus.
Results: In total, 119 outcome measures were presented to 33 experts from 18 countries. The recommended core set includes the Fugl–Meyer Motor Assessment and Action Research Arm Test for the upper extremity section; the Fugl–Meyer Motor Assessment, 10-m Walk Test, Timed-Up-and-Go, and Berg Balance Scale for the lower extremity section; and the National Institutes of Health Stroke Scale, and Barthel Index or Functional Independence Measure for the ADL/stroke-specific section. The Stroke Impact Scale was recommended spanning all ICF domains. Recommended measurement time points are days 2 ± 1 and 7; weeks 2, 4, and 12; 6 months poststroke and every following 6th month.
Discussion and Conclusion: Agreement was found upon a set of nine outcome measures for application in clinical motor rehabilitation poststroke, with seven measurement time points following the stages of poststroke recovery. This core set was specifically developed for clinical practice and distinguishes itself from initiatives for stroke rehabilitation research. The next challenge is to implement this clinical core set across the full stroke care continuum with the aim to improve the transparency, comparability, and quality of stroke rehabilitation at a regional, national, and international level.
Abstract
Background
Identifying predictors for general cognitive training (GCT) success in healthy older adults has many potential uses, including aiding intervention and improving individual dementia risk prediction, which are of high importance in health care. However, the factors that predict training improvements and the temporal course of predictors (eg, do the same prognostic factors predict training success after a short training period, such as 6 weeks, as well as after a longer training period, such as 6 months?) are largely unknown.
Methods
Data (N = 4,184 healthy older individuals) from two arms (GCT vs. control) of a three‐arm randomized controlled trial were reanalyzed to investigate predictors of GCT success in five cognitive tasks (grammatical reasoning, spatial working memory, digit vigilance, paired association learning, and verbal learning) at three time points (after 6 weeks, 3 months, and 6 months of training). Possible investigated predictors were sociodemographic variables, depressive symptoms, number of training sessions, cognitive baseline values, and all interaction terms (group*predictor).
Results
Being female was predictive for improvement in grammatical reasoning at 6 weeks in the GCT group, and lower cognitive baseline scores were predictive for improvement in spatial working memory and verbal learning at 6 months.
Conclusion
Our data indicate that predictors seem to change over time; remarkably, lower baseline performance at study entry is only a significant predictor at 6 months training. Possible reasons for these results are discussed in relation to the compensation hypothesis. J Am Geriatr Soc 68:‐, 2020.
Abstract
Head motion during magnetic resonance imaging (MRI) induces image artifacts that affect virtually every brain measure. In parallel, cross‐sectional observations indicate a correlation of head motion with age, psychiatric disease status and obesity, raising the possibility of a systematic artifact‐induced bias in neuroimaging outcomes in these conditions, due to the differences in head motion. Yet, a causal link between obesity and head motion has not been tested in an experimental design. Here, we show that a change in body mass index (BMI) (i.e., weight loss after bariatric surgery) systematically decreases head motion during MRI. In this setting, reduced imaging artifacts due to lower head motion might result in biased estimates of neural differences induced by changes in BMI. Overall, our finding urges the need to rigorously control for head motion during MRI to enable valid results of neuroimaging outcomes in populations that differ in head motion due to obesity or other conditions.
Abstract
Background and purpose:Diagnosing a patient with headache as a migraineur is critical for state-of-the-art migrainemanagement. Screening tools are imperative means to improve the diagnostic yield in the primary care settings andspecialized clinics. This study aims to translate and assess the diagnostic accuracy of a German version of theID Migraine™as a widely used and efficient screening instrument.
Methods:
The Functional Assessment of Chronic Illness Therapy translation methodology was used to translate theoriginal three-itemID Migraine™, including a fourth question for aura, from the English language into the German language.Diagnostic accuracy of the GermanID Migraine™and predictors of false screening results were assessed among patientspresenting to a headache outpatient clinic of a tertiary care center in Germany over a 6-month period.
Results:
The translation procedure yielded a harmonized GermanID Migraine™and its diagnostic accuracy was assessedin 105 patients (80 female, 46.5+17.2 years of age), including 79 patients (75.2%) with migraine. The three-item GermanID Migraine™provides a sensitivity of 99%, specificity of 68%, and positive and negative predictive values of 90% and 95%,respectively, using a cutoff of2. Positive and negative predictive values in a general headache population are estimated tobe 74% and 98%, respectively. The aura question identified 18 out of 20 migraineurs with aura.
Conclusions:
The GermanID Migraine™is an accurate screening tool for migraine even in a challenging population of aspecialized outpatient clinic. Its diagnostic accuracy indicates a potential utility for screening in primary health care.
Background: Granulocytes and monocytes are the first cells to invade the brain post stroke and are also being discussed as important cells in early neuroinflammation after seizures. We aimed at understanding disease specific and common pathways of brain-immune-endocrine-interactions and compared immune alterations induced by stroke and seizures. Therefore, we compared granulocytic and monocytic subtypes between diseases and investigated inflammatory mediators. We additionally investigated if seizure type determines immunologic alterations.
Material and Methods: We included 31 patients with acute seizures, 17 with acute stroke and two control cohorts. Immune cells were characterized by flow cytometry from blood samples obtained on admission to the hospital and the following morning. (i) Monocytes subpopulations were defined as classical (CD14++CD16−), (ii) intermediate (CD14++CD16+), and (iii) non-classical monocytes (CD14dimCD16+), while granulocyte subsets were characterized as (i) “classical granulocytes” (CD16++CD62L+), (ii) pro-inflammatory (CD16dimCD62L+), and (iii) anti-inflammatory granulocytes (CD16++CD62L−). Stroke patient's blood was additionally drawn on days 3 and 5. Cerebrospinal fluid mitochondrial DNA was quantified by real-time PCR. Plasma High-Mobility-Group-Protein-B1, metanephrine, and normetanephrine were measured by ELISA.
Results: HLA-DR expression on monocytes and their subpopulations (classical, intermediate, and non-classical monocytes) was reduced after stroke or seizures. Expression of CD32 was increased on monocytes and subtypes in epilepsy patients, partly similar to stroke. CD32 and CD11b regulation on granulocytes and subpopulations (classical, anti-inflammatory, pro-inflammatory granulocytes) was more pronounced after stroke compared to seizures. On admission, normetanephrine was upregulated in seizures, arguing for the sympathetic nervous system as inducer of immune alterations similar to stroke. Compared to partial seizures, immunologic changes were more pronounced in generalized tonic-clonic seizures.
Conclusion: Seizures lead to immune alterations within the immediate postictal period similar but not identical to stroke. The type of seizures determines the extent of immune alterations.
Alongside biological, psychological, and social risk factors, psychotic syndromes may berelated to disturbances of neuronal migration. This highly complex process characterizesthe developing brain of the fetus, the early postnatal brain, and the adult brain, as reflectedby changes within the subventricular zone and the dentate gyrus of the hippocampus,where neurogenesis persists throughout life. Psychosis also appears to be linked tohuman cytomegalovirus (HCMV) infection. However, little is known about the connectionbetween psychosis, HCMV infection, and disruption of neuronal migration. The presentstudy addresses the hypothesis that HCMV infection may lead to mental disordersthrough mechanisms of autoimmune cross-reactivity. Searching for common peptidesthat underlie immune cross-reactions, the analyses focus on HCMV and human proteinsinvolved in neuronal migration. Results demonstrate a large overlap of viral peptides withhuman proteins associated with neuronal migration, such as ventral anterior homeobox 1and cell adhesion molecule 1 implicated in GABAergic and glutamatergicneurotransmission. The presentfindings support the possibility of immune cross-reactivity between HCMV and human proteins that—when altered, mutated, orimproperly functioning—may disrupt normal neuronal migration. In addition, thesefindings are consistent with a molecular and mechanistic framework for pathologicalsequences of events, beginning with HCMV infection, followed by immune activation,cross-reactivity, and neuronal protein variations that may ultimately contribute to theemergence of mental disorders, including psychosis